ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 017,88
1,01%
Dow Jones
38 711,29
0,00%
DAX
18 596,97
0,97%
Brent Oil
77,965
1,11%
Bitcoin
71 029,39
0,57%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. TCR2 Therapeutics Inc (TCRR)

  7. TCR2 Therapeutics Inc (TCRR) Actualités

TCRR

TCR2 Therapeutics (TCRR)

TCR2 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TCRR
DateHeureSourceTitreSymboleSociété
12/06/202313h01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:TCRRTCR2 Therapeutics Inc
06/06/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:TCRRTCR2 Therapeutics Inc
05/06/202322h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322h46Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322h42Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322h11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202315h35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:TCRRTCR2 Therapeutics Inc
30/05/202322h22Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:TCRRTCR2 Therapeutics Inc
24/05/202322h57Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202313h17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202312h30GlobeNewswire Inc.TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
08/05/202322h05GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
06/05/202300h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TCRRTCR2 Therapeutics Inc
05/05/202322h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TCRRTCR2 Therapeutics Inc
20/04/202322h51Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202312h52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202312h17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202311h30GlobeNewswire Inc.TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
06/03/202312h00GlobeNewswire Inc.Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
08/02/202312h45GlobeNewswire Inc.TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202322h15GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202314h45GlobeNewswire Inc.TCR² Therapeutics Announces Pipeline Priorities for 2023NASDAQ:TCRRTCR2 Therapeutics Inc
23/11/202212h45GlobeNewswire Inc.TCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceNASDAQ:TCRRTCR2 Therapeutics Inc
18/11/202222h08Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:TCRRTCR2 Therapeutics Inc
09/11/202209h25TipRanksMizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202217h36TipRanksSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202212h45GlobeNewswire Inc.TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
07/11/202214h01GlobeNewswire Inc.TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNASDAQ:TCRRTCR2 Therapeutics Inc
19/10/202222h16Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:TCRRTCR2 Therapeutics Inc
29/09/202212h25TipRanksTCR2 Therapeutics (TCRR) Gets a Buy from H.C. WainwrightNASDAQ:TCRRTCR2 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TCRR

Dernières Valeurs Consultées

USOTC
NVTAQ
Invitae (CE)
BOV
S2QU34
Block
BIT
P1U2O4
NLBNPIT1U2O4 20240621 11
EU
R661S
R661S
ASX
ECTOC
Environmental Clean Tech...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés